In turn, the overexpression of AtGLR1.2 or AtGLR1.3 could improve the tolerance of mutants to cold stress by synthesizing endogenous JA (Zheng et al., 2018)
Can you send me the coverage criteria in writing?" 2025-2026 MEDICAID CHANGES States Ending Coverage Due to budget pressures and the high cost of GLP-1 medications, several states have announced they're ending or restricting Medicaid coverage for weight loss drugs: California (Medi-Cal) Ending Coverage January 1, 2026 Beginning January 1, 2026, Medi-Cal will no longer cover GLP-1 medications for weight loss
GLP-1 receptor activation directly engages this same pathway
Tirzepatide Retatrutide looks better than tirzepatide because it works like three hormones, not two
Because it is mixed in a pharmacy rather than a factory, there can be slight variations in the inactive ingredients
Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial